Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com - Stifel maintained its Buy rating and $11.00 price target on Compass Therapeutics (NASDAQ:CMPX), currently trading at $2.92, following investor meetings with the company’s management team. The biotech company, with a market capitalization of $373 million, enjoys strong analyst support with a consensus "Strong Buy" recommendation. According to InvestingPro data, analyst price targets range from $6 to $32, suggesting significant upside potential.
The research firm views the extended timeline for overall survival event accrual in the Phase 2/3 COMPANION-002 trial as a positive development. This trial is evaluating paclitaxel with or without tovecimig in second-line biliary tract cancer patients.
Management now projects topline data disclosure in the fourth quarter of 2025, which implies over 19 months of median follow-up. Stifel notes this extended follow-up is significant in a disease setting where control arm median overall survival rarely exceeds approximately 6 months.
While investor focus remains on the COMPANION-002 trial results, Stifel believes upcoming data disclosures for two other compounds in the second half of 2025 are underappreciated potential catalysts. These include Phase 1 dose-escalation data for CTX-8371, a PD-1xPD-L1 bispecific antibody, and preclinical data for CTX-10726, a PD-1xVEGF-A bispecific.
The firm also expressed increasing interest in the multi-modal mechanism of action underlying CTX-837, another compound in Compass Therapeutics’ pipeline.
In other recent news, Compass Therapeutics has initiated a clinical trial for tovecimig, a bispecific antibody, in treating biliary tract cancer (BTC). The trial, conducted at The University of Texas MD Anderson Cancer Center, aims to assess the drug’s efficacy when combined with a standard regimen of gemcitabine, cisplatin, and durvalumab. This study involves a safety run-in phase followed by an expansion phase, targeting approximately 50 patients with unresectable or metastatic BTC. The primary objectives include evaluating the six-month progression-free survival rate and the drug’s safety and tolerability. This development complements ongoing Phase 2/3 studies where tovecimig recently met its primary endpoint.
Additionally, H.C. Wainwright has maintained its Buy rating and $24 price target for Compass Therapeutics, reflecting confidence in the potential of tovecimig. The firm’s endorsement follows the presentation of new preclinical data at the American Association for Cancer Research conference. The data highlighted the potential benefits of combining CTX-471 with tovecimig in treating checkpoint-refractory solid tumors. These recent developments underscore Compass Therapeutics’ ongoing efforts to advance its therapeutic pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.